Cassava Sciences Stock Soared 130% on Monday Followed by Positive Results of New Alzheimer’s Phase 2 Trials
The biotech company Cassava Sciences updates that its Alzheimer’s drug, sumifilam, recorded positive results in treating Alzheimer’s patients in a phase 2 study. Cassava Sciences Inc. (SAVA) shares were on a roll in the last trading session on Monday after the company reported that it has obtained positive outcomes from its Phase 2 study of a […]